Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer
ConclusionsHistorical survival in patients with advanced and metastatic pancreas cancer is poor. Results of this DDR-subset of patients do show significantly superior outcomes, likely secondary to exposure to platinum drugs. This data, alongside other similar cohorts, would favor the DDR-genes being a predictive marker with improved survival if exposed to these drugs and the new class of drugs, PARP-inhibitors.
Source: Hereditary Cancer in Clinical Practice - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Genetics | Pancreas | Pancreatic Cancer